We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Autonomous Microchannel Analyzer Combines with Smartphone for Off-Site Disease Diagnostics

By LabMedica International staff writers
Posted on 18 Feb 2020
Print article
Image: The photo shows a portable lab that plugs into a smartphone to diagnose diseases like malaria or coronavirus (Photo courtesy of Joseph Fuqua II, University of Cincinnati Creative Services)
Image: The photo shows a portable lab that plugs into a smartphone to diagnose diseases like malaria or coronavirus (Photo courtesy of Joseph Fuqua II, University of Cincinnati Creative Services)
A novel microchannel capillary flow assay platform for detection of pathogenic microorganisms or other antigens combines with a smartphone for display, data transfer, storage, and analysis.

Investigators at the University of Cincinnati (OH, USA) built the microchannel capillary flow assay (MCFA) platform to perform chemiluminescence based ELISA tests with lyophilized chemiluminescent reagents. The MCFA platform exploits the ultra-high sensitivity of chemiluminescent detection while eliminating the shortcomings associated with liquid reagent handling, control of assay sequence, and user intervention.

Functionally designed microchannels along with adequate hydrophilicity provided by the saliva sample produce a sequential flow of assay reagents, and the device autonomously performs the ultra-high sensitive chemiluminescence based ELISA. An attached smartphone for display, data transfer, storage and analysis, as well as the source of power, enabled the development of a point-of-care-testing (POCT) analyzer for disease diagnostics.

The current report described the use of the MCFA device for detection of the malaria biomarker PfHRP2. For this antigen a limit of detection (LOD) of eight nanograms per milliliter was achieved, which is sensitive enough to detect active malarial infection.

Furthermore, the investigators assert that the device can be adapted to diagnose other infectious diseases such as coronavirus, HIV or Lyme disease or innumerable other health conditions such as depression and anxiety.

"The performance is comparable to laboratory tests. The cost is cheaper. And it is user-friendly," said senior author Dr. Chong Ahn, distinguished university research professor at the University of Cincinnati. "We wanted to make it simple so anyone could use it without training or support. Right now it takes several hours or even days to diagnose in a lab, even when people are showing symptoms. The disease can spread."

The MCFA device was described in the January 27, 2020, online edition of the journal Microsystems & Nanoengineering.

Related Links:
University of Cincinnati

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Pipet Controller
Stripettor Pro
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.